Dyne Therapeutics Inc

DYN

Company Profile

  • Business description

    Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

  • Contact

    1560 Trapelo Road
    WalthamMA02451
    USA

    T: +1 781 786-8230

    E: [email protected]

    https://www.dyne-tx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    206

Stocks News & Analysis

stocks

Wildly overvalued ASX stock is skating on thin ice

This company dominates its industry and could be flirting with regulatory intervention.
stocks

Uber flexes its network effect and delivers strong result

Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks

Ask the analyst: Are Qantas shares a value trap?

Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,102.009.10-0.10%
CAC 407,717.5282.491.08%
DAX 4024,249.13324.771.36%
Dow JONES (US)44,048.03145.09-0.33%
FTSE 1009,108.4355.88-0.61%
HKSE25,081.63171.000.69%
NASDAQ21,320.72151.300.71%
Nikkei 22541,059.15264.290.65%
NZX 50 Index12,887.106.940.05%
S&P 5006,359.3914.330.23%
S&P/ASX 2008,831.4012.30-0.14%
SSE Composite Index3,639.675.670.16%

Market Movers